Day+100 Survival and Safety Results from a Defibrotide Expanded-Access Program for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS): Final Results

VOD/SOS is a potentially life-threatening complication of hematopoietic stem cell transplant (HSCT) conditioning or chemotherapy; VOD/SOS with multi-organ dysfunction (MOD) may be associated with>80% mortality. Defibrotide is approved for treating hepatic VOD/SOS with renal/pulmonary dysfunction post-HSCT in the US, and for treating severe hepatic VOD/SOS post-HSCT in the EU.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Nancy Kernan, Angela Smith, Joseph Antin, Leslie Lehmann, Sergio Giralt, Robert Ryan, Robin Hume, William Tappe, Paul Richardson Source Type: research